INT-747 is used primarily in the treatment of liver-related diseases, particularly those involving fibrosis and cholestasis. It acts as a selective agonist for the farnesoid X receptor (FXR), which plays a key role in regulating bile acid metabolism, inflammation, and liver function. By activating FXR, INT-747 helps reduce bile acid synthesis, enhances hepatoprotection, and decreases liver inflammation and fibrosis progression. It has shown promise in preclinical models of non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and other chronic liver conditions. Its ability to modulate metabolic and inflammatory pathways makes it a candidate for therapeutic development in metabolic liver diseases.